MONTEVIDEO, Uruguay, Dec. 15, 2017 /PRNewswire/ -- BIOTOSCANA INVESTMENTS S.A. ("Company" or "GBT") (B3: GBIO33), a leadingbiopharmaceutical company in Latin America, announces to its shareholders and the market in general that has hired Ivan French as Executive Vice President of Research and Development.
According to Mariano Garcia-Vali˝o, CEO of GBT, "Ivan will bring renewed efforts into our proprietary product and clinical development and enhance our abilities to reach further-up into the R&D chain into earlier development phases, where more promising products and rarer opportunities are available."
Mr. French will be responsible for GBT's clinical research teams, central regulatory teams and central pharmacovigilance teams, both legacy LKM and legacy DOSA.
About GBT-Grupo Biotoscana GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT's strong portfolio combines world-class licenses and proprietary products. To find out more, please visit www.grupobiotoscana.com.
Contacts:GBT - Grupo BiotoscanaMelissa Angelini+55 11 5090 5927 firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/notice-to-the-market-grupo-biotoscana-announces-hiring-of-executive-vice-president-of-rd-300572231.html
SOURCE Grupo Biotoscana
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All